SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis - PubMed
9 hours ago
- #Liver cirrhosis
- #SGLT2 inhibitors
- #Type 2 diabetes
- SGLT2 inhibitors (SGLT2is) were compared with DPP4 inhibitors (DPP4is) in patients with type 2 diabetes (T2D) and liver cirrhosis.
- The study used data from Taiwan's National Health Insurance Database (2016-2023) involving 24,259 patients.
- SGLT2i use was associated with significantly lower risks of end-stage kidney disease (ESKD), acute kidney injury (AKI), and major adverse cardiovascular events (MACE).
- Additional benefits included reduced risks of all-cause mortality and hepatic decompensation events.
- The findings suggest SGLT2is provide cardiorenal and hepatic protection in high-risk T2D patients with liver cirrhosis.